Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS

Christina Rautenberg1 | Michael Lauseker2 | Jennifer Kaivers1 | Paul Jäger1 | Carolina Fischermanns1 | Sabrina Pechtel1 | Rainer Haas1 | Guido Kobbe1 | Ulrich Germing1 | Thomas Schroeder1,3

Abstract
Objective: As peripheral blood (PB) Wilm's Tumor 1 (WT1)-mRNA expression is established as MRD-marker during conventional AML chemotherapy, impact of pretransplant WT1 expression remains unclear. Therefore, we aimed to assess prognostic impact of pretransplant WT1 expression on post-transplant outcome in patients with AML/MDS.

Methods: In 64 AML/MDS patients, pretransplant WT1 expression was retrospectively analyzed using a standardized assay offering high sensitivity, specificity, and a validated cut-off. Patients were divided into three groups determined by pretransplant remission and WT1 expression. Post-transplant outcome of these groups was compared regarding cumulative incidence of relapse (CIR), relapse-free (RFS), and overall survival (OS).

Results: Pretransplant forty-six patients (72%) showed hematologic remission, including 21 (46%) MRD-negative and 25 (54%) MRD-positive patients indicated by WT1 expression, while 18 refractory patients (28%) showed active disease. Two-year estimates of post-transplant CIR, RFS, and OS were similar in MRD-positive (61%, 37%, 54%) and refractory patients (70%, 26%, 56%), but significantly inferior compared with MRD-negative patients (10%, 89%, 90%). After multivariable adjustment, pretransplant MRD negativity measured by WT1 expression retained its prognostic impact on CIR (P = .008), RFS (P = .005), and OS (P = .049).

Conclusions: PB WT1 expression represents a useful method to estimate pretransplant MRD, which is highly predictable for post-transplant outcome and may help improving peri-transplant management in AML/MDS patients.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment approach for many patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). In patients with AML, allo-HSCT is most effective when performed in complete remission (CR), which is usually achieved after intensive chemotherapy (CTX). The role of pretransplant cytoreduction in advanced MDS or AML derived from MDS (sAML) is still a matter of debate, but those 20% to 50% of patients, who achieve remission either after CTX or hypomethylating agents (HMA), have a good chance to achieve long-term survival. Still, even in the absence of morphologically detectable disease at the time of transplant, relapse remains the main cause of treatment failure, suggesting that conventional morphology is incapable to detect clinically relevant amounts of malignant cells, which subsequently drive post-transplant relapse.

In accordance with this, several groups have shown in general that the presence of submicroscopic levels of leukemia (ie, measurable residual disease, MRD) detected by multiparametric flow cytometry (MFC), PCR-, or NGS-based techniques at the time of transplantation offers prognostic information in patients undergoing allo-HSCT in hematologic remission. However, the following methodological and biological aspects limit their use in clinical routine: (1) molecular aberrations suitable for sensitive MRD monitoring are only present in subgroups of patients and/or instable during the course of disease; (2) lack of reproducible standardized assays and/or high technical and resource-consuming efforts; (3) the need for bone marrow (BM) as optimal sample source. In contrast, we and other have demonstrated that measurement of Wilms Tumor 1 (WT1)-mRNA expression offers several of these advantageous properties, as it is present in about 80 to 90% of patients with AML and advanced MDS and can be quantitatively measured in peripheral blood (PB) using a standardized assay with high sensitivity and specificity. In the current retrospective analysis, we aimed to determine the prognostic impact of pretransplant MRD detected by PB WT1-mRNA expression on post-transplant outcome in patients with AML or MDS undergoing allo-HSCT in hematologic remission.

METHODS

2.1 Study Design
This retrospective analysis included 64 patients with AML (n = 50) without recurrent genetic abnormalities, advanced MDS, or chronic myelomonocytic leukemia (CMML) (n = 14), who were allografted at our center between March 2013 and January 2020 either in hematologic CR (n = 46, 72%) or with active disease after being refractory to chemotherapy (n = 18, 28%). Further inclusion criteria were PB WT1-mRNA overexpression at diagnosis and available information about PB WT1-mRNA expression level before transplantation. Post-transplant outcome in terms of overall (OS) and relapse-free survival (RFS) as well as relapse incidence (CIR) and non-relapse mortality (NRM) were compared between patients with MRD-positive (CRMRD+) and MRD-negative (CRMRD-) CR prior transplant assessed by PB WT1-mRNA expression status as well as 18 refractory patients with morphological evidence of disease at transplantation. All patients gave written informed consent according to the Declaration of Helsinki, and the analysis was approved of the institutional review board (approval numbers: 3973, 3768 and 3541).

2.2 Quantitative assessment of peripheral blood cell WT1-mRNA expression
Quantitative assessment of WT1-mRNA expression in PB mononuclear cells was performed using the Ipsogen® WT1 ProfiQuant® Kit according to the manufacturers’ instructions with technical and quality settings as previously described. This plasmid-based, standardized, ELN-certified assay offers a validated cut-off level of 50 WT1 copies/10⁶ ABL copies in PB to distinguish between normal and overexpression of WT1-mRNA. This cut-off was established and validated using 620 diagnostic and 129 follow-up samples from 504 AML patients and 118 peripheral blood samples from healthy volunteers in a systemic evaluation of nine published and in-house PCR-based assays in a network of 11 laboratories. As another advantage, this assay includes specific plasmids, primers, and probes, which enables stable and checkable performance of the assay and exact quantification of WT1-mRNA expression within each sample via standard curve. These properties make results and the specific cut-off reproducible and comparable between different laboratories when using this assay. All patients with CR prior transplant were categorized for post-transplant outcome analyses based on this validated cut-off level into those with normalized (defined as <50 WT1 copies/10⁶ ABL copies) PB WT1-mRNA expression representing CRMRD, and those with WT1-mRNA overexpression (defined as >50 WT1 copies/10⁶ ABL copies) reflecting CRMRD+. The results from MRD analyses were available to the transplant team.

2.3 Definitions and Response Criteria
Remission status prior transplant and conditioning intensity was defined as previously reported. Furthermore, depth of remission regarding MRD was defined as described above. Post-transplant hematologic relapse was defined as ≥5% BM blasts, detection of
blasts in PB, and/or extramedullary disease. Molecular relapse after allo-HSCT was defined as presence of disease-specific cytogenetic aberrations, reoccurrence of known mutations in at least 1% of reads, a decrease in donor chimerism <95%, evidence of a mixed XY-FISH of >4% residual recipient cells, or an increase of PB WT1-mRNA expression above the cut-off of 50 copies per 10^6 ABL copies detected at two separate time points during an interval of 14 days and in absence of any criterion defining hematologic relapse. Both hematologic and molecular relapse were appraised as event for CIR and RFS.

2.4 | Statistical analyses

Data lock for this analysis was June 1, 2020. For categorical variables, frequencies were given and differences were estimated applying cross tabulation and Fisher’s exact test. For continuous variables, medians (ranges) were given and the Mann-Whitney test was used to detect differences. OS was calculated as date from allo-HSCT to death from any cause or last follow-up in survivors. RFS was defined as time from allo-HSCT until (i) molecular or hematologic relapse or (ii) death with those censored at last contact who were alive and had not experienced relapse until then. Both OS and RFS were estimated using Kaplan-Meier method, and log-rank test was used for univariate comparisons. Relapse incidence and non-relapse mortality (NRM) were considered as competing risks and calculated using cumulative incidence (CI) estimates employing Gray test for univariate comparisons. Multivariate analysis was performed using a multiple Cox regression model with a step-wise backward procedure and included only variables influencing outcome in univariate analysis with a P-value <.1. For relapse incidence and NRM variables, multivariate analyses have to be interpreted as a cause-specific hazards model. In all analyses, a P-value <.05 was considered to be statistically significant. Statistical analyses were performed using GraphPad Prism® 5.01 (GraphPad Software Inc, La Jolla, USA), SPSS Statistic for Windows (SPSS Inc Chicago, IL), and R 4.0.0.

3 | RESULTS

3.1 | Patient Characteristics

For this analysis, we identified 46 patients with MDS/MPN (n = 8, 17%), sAML (n = 14, 30%), therapy-related (n = 3, 7%), or de novo AML (n = 21, 46%) with PB WT1-mRNA overexpression (median 2187.6, range 76 to 2433.1 WT1 copies per 10^6 ABL copies) at diagnosis, who underwent first allo-SCT in hematologic CR at our institution between March 2013 and January 2020. Besides WT1-mRNA overexpression at diagnosis, these patients had no molecular marker such as NPM1 or other recurrent genetic abnormalities suitable for sensitive PCR-based MRD monitoring. As indicated in Table S1, individual patients exhibited mutations in genes such as FLT3, DNMT3A, or ASXL1. However, these molecular markers are not optimal for MRD monitoring due to instability during course of disease, lack of sensitive assays in clinical routine, and/or association with clonal hematopoiesis. Detailed information regarding patients and transplant characteristics is summarized in Tables 1 and 2. Patients had achieved first (n = 44, 96%) or second CR (n = 2, 4%) after treatment with a median of 2 (range: 1-5) cycles of intensive CTX (n = 39, 85%) or after a median of 2 (range: 1-7) cycles of HMA (n = 7, 15%). Of these 46 patients, 21 (46%) were MRD-negative indicated by normalized PB WT1-mRNA values (<50 WT1 copies per 10^6 ABL copies; median 7.3, range 0 to 42.6 WT1 copies per 10^6 ABL copies), while 25 patients (54%) still showed WT1-mRNA overexpression in PB (≥50 WT1 copies per 10^6 ABL copies; median 149, range 52 to 4002.9 WT1 copies per 10^6 ABL copies) thus being MRD-positive. The majority of patients received peripheral blood stem cells (n = 43, 93%) from a HLA-matched unrelated donor (n = 27, 59%) after reduced intensity conditioning (RIC, n = 30, 65%), whereas 16 patients (35%) underwent allo-HSCT after myeloablative conditioning according to the definitions determined by Bacigalupo and colleagues.27 Further details regarding conditioning regimen of the entire study population including refractory patients are displayed in Table S2. Median time between diagnosis and allo-HSCT was 3.7 months (range, 0.7 to 37.8) and was similar between CRMRD+ patients (median 3.6 months, range 0.7 to 18.6 months) and CRMRD- patients (median 3.7 months, range 2.2 to 37.8 months, P = .772). Median time between MRD assessment and allo-HSCT was 21 days (range, 4 to 70) and also comparable between CRMRD-patients (median 21 days, range 7-69) and CRMRD- patients (median 20 days, range 4 to 70, P = .674). Furthermore, with the exception of a significantly higher frequency of an abnormal karyotype, there were no differences between patients with CRMRD+ and CRMRD- regarding common patient-, disease-, or transplant-related factors (Table 2). Eighteen additional patients with AML, MDS, or CMML were primary refractory to induction chemotherapy and underwent allo-SCT during the same time-period with active hematologic disease. Baseline characteristics of these 18 patients were comparable to the 46 patients transplanted in CR (Table 2) including the fact that with except for WT1-mRNA overexpression they neither exhibited a molecular marker suitable for sensitive PCR-based MRD monitoring.

3.2 | Outcome after allo-HSCT

A total of 14 deaths, 21 relapses, and 2 NRM events contributed to the probability estimates for OS, RFS, relapse, and NRM stratified by MRD status in the 46 patients with CR at transplant. After a median post-transplant follow-up period of 33.7 months (range: 2.8-67.3 months), the 2-year OS, RFS, CIR, and NRM rate of these 46 patients with hematologic CR was 68% [95% CI: 51%-80%], 58% [95% CI: 41%-72%], 41% [95% CI: 27%-58%], and 4% [95% CI: 1%-17%], respectively (Figure 1). As indicated in Figure 2, in univariate analysis, the estimates for OS (two year probability: 54% vs 90%, log-rank P = .03), RFS (two year probability: 37% vs 89%, log-rank P < .01), and CIR (two year probability: 61% vs 10%, Gray test P < .01) significantly
TABLE 1 Patients demographics and transplant characteristics

| Characteristic                        | Remission status prior allo-HSCT | Refractory (n = 18) | Refractory (n = 18) | P  |
|---------------------------------------|----------------------------------|--------------------|--------------------|----|
|                                       | CR (n = 46)                      | No.    %     | No.    %     |                |
| Age, median (range), y                | 58 (21-73)                       | 59 (27-69)        | .61                |
| Gender                                |                                  |                    |                    | .78 |
| Male                                  | 25                               | 54                 | 11                 | 61  |
| Female                                | 21                               | 46                 | 7                  | 49  |
| WHO 2016 diagnosis^                  |                                  |                    |                    |    |
| AML                                   |                                  |                    |                    |    |
| AML-MRC                               | 14                               | 30                 | 7                  | 39  | .56 |
| t-MN                                  | 3                                | 7                  | 0                  | 0   | .55 |
| AML NOS                                | 20                               | 43                 | 5                  | 28  | .27 |
| Myeloid sarcoma                       | 1                                | 2                  | 0                  |     | >.99|
| MDS/MPN                               |                                  |                    |                    |    |
| MDS-EB2                                | 6                                | 13                 | 5                  | 28  | .27 |
| CMML                                  | 2                                | 4                  | 1                  | 6   | >.99|
| Karyotype                             |                                  |                    |                    |    |
| Normal                                | 22                               | 48                 | 7                  | 39  | .58 |
| Aberrant                              | 24                               | 52                 | 11                 | 61  |
| Complex                               | 10                               | 22                 | 7                  | 39  | .21 |
| ELN cytogenetic/molecular genetic risk^b|                                  |                    |                    |    |
| Favorable                             | 0                                | 0                  | 0                  | 0   | >.99*|
| Intermediate                          | 15                               | 39                 | 5                  | 41  |
| Adverse                               | 22                               | 58                 | 7                  | 58  |
| Missing                               | 1                                | 3                  | 0                  | 0   |
| IPSS-R cytogenetic Risk^c             |                                  |                    |                    |    |
| Very/good                             | 0                                | 0                  | 2                  | 40  | .08f|
| Intermediate                          | 1                                | 17                 | 2                  | 40  |
| Poor/very poor                        | 5                                | 83                 | 1                  | 20  |
| Disease Status at allo-HSCT^d          |                                  |                    |                    |    |
| CR1                                   | 44                               | 96                 | -                  |     |
| CR2                                   | 2                                | 4                  | -                  |     |
| MRD Status prior transplant^e         |                                  |                    |                    |    |
| CRMRD+                                | 25                               | 54                 | 18                 | 100 |
| CRMRD-                                | 21                               | 46                 | -                  | -   |
| Conditioning^f                        |                                  |                    |                    |    |
| Myeloablative                         | 16                               | 35                 | 7                  | 39  | .78 |
| Dose-reduced                          | 30                               | 65                 | 11                 | 61  |
| HCT-CI                                |                                  |                    |                    |    |
| Low                                   | 27                               | 59                 | 11                 | 61  | >.99|
| Int/high                              | 19                               | 41                 | 7                  | 39  |
| Donor Type                            |                                  |                    |                    |    |
| Matched related                       | 9                                | 20                 | 5                  | 28  | .51 |
| Matched unrelated                     | 27                               | 58                 | 9                  | 50  | .58 |
| Mismatched related                    | 1                                | 2                  | 0                  | 0   |

(Continues)
Focusing on other patient-, disease-, or transplant-related parameters, we found that in addition to the MRD status, the presence of a complex karyotype, high-risk genetics, and the use of a related donor were associated with a shorter OS in univariate analysis. A complex KT was also the only factor besides MRD status, which showed an impact on RFS and relapse incidence in univariate analysis (Table S3). Due to the low number of events (n = 4), no parameter associated with NRM could be ascertained.

In multivariate analyses, pretransplant MRD negativity measured by WT1-mRNA expression was associated with longer RFS, lower relapse incidence, and longer OS than MRD positivity. While no other parameter besides MRD status influenced RFS and relapse

### TABLE 2  Comparison of patient- and transplant-related characteristics according to MRD status prior transplant assessed by WT1-mRNA expression in patients with hematologic complete remission

| Characteristic                                      | All (100%) | CRMRD+ | CRMRD- | P   |
|-----------------------------------------------------|------------|--------|--------|-----|
| No. of patients                                     | 46 (100%)  | 25     | 21     |     |
| Follow-up, median (range), mo                       | 33.7 (2.8-67.3) | 37.4 (2.8-59.4) | 26.3 (2.9-67.3) | .77 |
| Age, median (range), y                               | 58 (21-73) | 61 (24-69) | 56 (21-52) | .14 |
| Gender                                              |            |        |        | >.99|
| Male                                                | 22 (48%)   | 12     | 10     |     |
| Female                                              | 24 (52%)   | 13     | 11     |     |
| WHO 2016 diagnosis                                 |            |        |        |     |
| AML                                                 |            |        |        |     |
| AML-MRC                                              | 14 (30%)   | 10     | 4      |      |
| De novo AML (therapy rel AML, AML NOS, Myeloid sarcoma) | 24 (52%)   | 10     | 14     |      |
| MDS/MPN                                             |            |        |        |     |
| MDS-EB2                                              | 6 (13%)    | 4      | 2      |     |
| CMML                                                | 2 (4%)     | 1      | 1      |     |
| Karyotype                                           |            |        |        |     |
| Normal                                              | 22 (48%)   | 8      | 14     | .04 |
| Aberrant                                            | 24 (52%)   | 17     | 7      | .31 |
| Complex                                             | 10 (22%)   | 7      | 3      |     |
| Cytogenetic risk category                           |            |        |        |     |
| Low/int                                             | 16 (35%)   | 7      | 9      | .36 |
| High                                                | 27 (59%)   | 16     | 11     |     |
| Missing                                             | 3 (7%)     | 2      | 1      |     |
| WT1-mRNA expression at diagnosis, median (range)    | 2188 (74-26433) | 2140 (94-19547) | 2397 (74-26433) | .76 |
| FLT3-ITD mutation status                            |            |        |        |     |
| mut and high ratio                                  | 8 (17%)    | 3      | 5      | .45 |
| wt or mut and low ratio                             | 31 (67%)   | 17     | 14     |     |
| Missing                                             | 7 (15%)    | 5      | 2      |     |
| Time to between diagnosis to allo-HSCT, months, median (range) | 3.7 (0.7-37.8) | 3.6 (0.7-18.8) | 3.7 (2.2-37.8) | .74 |
| HCT-CI                                              |            |        |        |     |
| Low                                                 | 27 (59%)   | 12     | 15     | .14 |
| Int/high                                            | 19 (41%)   | 13     | 6      |     |
| Conditioning                                        |            |        |        |     |
| Myeloablative                                       | 16 (35%)   | 7      | 9      | .36 |
| Dose-reduced                                        | 30 (65%)   | 18     | 12     |     |
| Donor Type                                          |            |        |        |     |
| Related                                             | 10 (22%)   | 5      | 5      | >.99|
| Unrelated                                           | 36 (78%)   | 20     | 16     |     |

(Continues)
incidence, the use of a related donor was confirmed as predictor for shorter OS (Table 3).

3.3 Relapse pattern and salvage therapy

Of the 46 patients with hematologic remission at allo-SCT, twenty-one (46%) experienced either molecular (n = 8, 38%) or hematologic (n = 13, 62%) relapse after a median of 11 months (range, 1-66 months). This included 18 (86%) of CRMRD+ patients and 3 (14%) of CRMRD- patients (Table S4). Of the 25 CRMRD- patients, 24 achieved MRD negativity after transplant, while one patient did not achieve MRD negativity and immediately showed disease progression. Of the remaining 17 relapses within the CRMRD+ cohort, 14 showed rise of WT1-mRNA expression at the time of relapse, while 3 patients remained below the validated cut-off of 50 WT1-mRNA copies, thus being in excellent agreement with our previous results. All 3 patients in the CRMRD- cohort, who relapsed after allo-SCT, showed rise of WT1-mRNA expression at relapse (Figure S1). Of interest, the time to relapse did not differ between CRMRD+ patients and those relapsing patients, who had undergone allo-HSCT with active hematologic disease (median time 3.8 months vs 4.3 months, P = .55). Nineteen of the 21 relapsing patients (90%) received a salvage therapy consisting of HMA and donor lymphocyte infusions (DLI), which induced CR in 9 of them (47%), while the 2 other patients received radiotherapy and DLI or best supportive care, respectively. This also includes all 8 patients with molecular relapse. All of them were treated with HMA at the stage of molecular relapse, which led to CR in 5 (63%) of them.

4 DISCUSSION

The results from this analysis show that measurement of PB WT1-mRNA expression using an ELN-certified assay enables determination of MRD in patients with hematologic remission prior transplant,
who do not carry another marker suitable for MRD monitoring in clinical routine, and thereby facilitates prediction of post-transplant relapse and outcome.

The finding that the presence of MRD prior allogeneic transplantation in patients with AML and MDS is associated with higher relapse risk and poorer survival after transplant is not new. This has already been demonstrated for the use of MFC, PCR-based analyses in molecular defined subgroups as exemplified in NPM1-mutant AML and NGS. Thus, our results obtained by measurement of PB WT1-mRNA expression are in agreement with these above mentioned methods as well as with studies regarding WT1-mRNA, which employed non-standardized in-house assays or used BM as sample source. However, determination of WT1-mRNA expression may have some advantages over the above mentioned methods: Molecular markers approachable by sensitive PCR assays such as NPM1 (~25%) or core-binding factor aberrations (~10%) are only present in subgroups of patients. Furthermore, markers such as FLT3 mutations are instable during the course and therefore suboptimal and not recommended for MRD monitoring. In contrast, WT1-mRNA overexpression is found in 80 to 90% of patients with AML and advanced MDS as well as stable during the course and consequently recommended if no other suitable marker is

---

**TABLE 3** Impact of clinical parameters on outcome after allogeneic transplantation for MDS/MPN and AML—multivariate analysis

| Variable                          | Cumulative incidence of relapse (CIR) | Relapse free survival (RFS) | Overall survival (OS) |
|----------------------------------|--------------------------------------|-----------------------------|-----------------------|
| Diagnosis                        |                                      |                             |                       |
| MDS/MPN/sAML vs de novo AML      |                                      |                             |                       |
| Karyotype                        |                                      |                             |                       |
| Complex vs not complex           |                                      |                             |                       |
| MRD status prior Tx*             |                                      |                             |                       |
| CR<sub>M</sub> vs CR<sub>M</sub> | <0.01                                | <0.01                       | 0.05                  |
| Donor                            |                                      |                             |                       |
| Related vs unrelated             |                                      |                             |                       |

Abbreviations: AML, acute myeloid leukemia; CR, complete remission; HR, hazard ratio; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasia; MRD, minimal residual disease; ns, not significant; OS, overall survival; RFS, relapse-free survival; sAML, secondary AML; Tx, transplant; y, years; “-” means not applicable.

*Regarding WT1-mRNA expression (MRD+ = ≥50 WT1 copies/10<sup>4</sup> ABL copies; MRD- = <50 WT1 copies/10<sup>4</sup> ABL copies).
available.

Besides this broad applicability, the availability of a standardized assay with a reproducible cut-off value and an assay-given sensitivity of 1:10^4 are another advantage of WT1-mRNA monitoring, especially in comparison with MFC. Error-corrected NGS approaches overcome some of these limitations, as they offer high sensitivity and broad applicability if several markers are used in each patient. Nevertheless, biological aspects have to be considered and may hamper interpretation of results from NGS-based approaches. In detail, persistence of mutations in genes such as DNMT3A, TET2, and ASXL1 (so-called DTA mutations) may be associated with preexisting clonal hematopoiesis and did not seem to have prognostic implications post-transplant outcome. In other cases, persistence of these mutations may also be a consequence of persistence in differentiated cells or germ line origin. Furthermore, high technical and resource-consuming demands as reflected by a realistic turnaround time of 2-3 weeks have limited the wide use of NGS in clinical routine so far. In further support of its practicability, the turnaround time for WT1-mRNA measurement in our routine is 4 days (range: 2-7 days, data not shown). Finally, in contrast to the other MRD methods, WT1-mRNA expression can be sensitively measured in PB thereby enabling frequent monitoring with sustained patient comfort.

The results from our analysis do not only indicate that measurement of PB WT1-mRNA expression is a practicable and valuable approach to measure MRD and to estimate post-transplant relapse risk and survival. They also point toward two other important aspects: (1) the outcome in terms of OS, RFS, and relapse incidence as well as the time to relapse in patients with hematologic remission, but detectable MRD (CR_MRD) is as worse as the outcome of those refractory patients with hematologic evidence of disease. This suggests that the presence of MRD is not only a quantitative marker reflecting low detectable disease burden, but in particular also a biological property of the leukemic cells and a qualitative indicator of an intrinsic disease resistance. (2) This triggers the question how we should therapeutically address the issue of MRD positivity prior transplant in our patients in the future. One option may be the incorporation of novel compounds such as CPX-351 or venetoclax-based combinations either as first-line therapy to induce higher rates of MRD negativity or as salvage therapy in MRD-positive patients prior transplant. Secondly, intensification of the conditioning regimen if feasible may also help to overcome the negative prognostic impact of MRD, as recently demonstrated. Finally, prophylactic or preemptive treatment strategies after transplantation, for example discontinuation of immunosuppression and/or DLI, hypomethylating agents, or FLT3 inhibitors may also reduce relapse risk and improve outcome of MRD-positive patients. The latter may explain why in our analysis the presence MRD prior transplant was associated with higher relapse incidence and lower RFS, but only with borderline significance with lower OS in multivariate analysis, since 7 patients (39%) relapsing after allo-SCT could be successfully treated with HMA and DLI.

In summary, measurement of PB WT1-mRNA expression with a standardized assay is a practicable and efficient approach to sensitively assess MRD prior transplant, which is applicable in the majority of patients with AML and MDS independent from the molecular profile, enables refined estimation of relapse risk and survival, and may help to optimize transplantation and post-transplant management.

ACKNOWLEDGMENTS

The authors thank the staff of the Transplantation Unit of the Department of Hematology, Oncology, and Clinical Immunology for the excellent patient care. Open Access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTEREST

A Rotorgene PCR cycler was provided free of charge by Qiagen for routine use in this study. No other financial or logistic support was provided by the company for this retrospective analysis. C. R. received financial travel support from Celgene Deutschland GmbH. T. S. received financial travel support, lecture fees, research funding, and participated in advisory boards for Celgene GmbH. TS received financial travel support, lecture fees, and participated in advisory boards for Janssen-Cilag GmbH. UG received lecture fees from Celgene Deutschland GmbH, Novartis, Jazz Pharmaceuticals and Janssen-Cilag GmbH. UG received research funding from Celgene Deutschland GmbH and Novartis. J. K. received travel support from Jazz Pharmaceuticals and Novartis.

AUTHOR CONTRIBUTION

CR and TS conceptualized the study and writing—original draft. CR, ML, UG, and TS involved in formal analysis and investigation. CR, PJ, CF, SP, and TS involved in methodology. CR and ML visualized the study. CR, JK, RH, GK, UG, and TS involved in writing—review and editing. All authors involved in final approval of the manuscript.

DATA AVAILABILITY STATEMENT

Datasets generated and analyzed for study can be made available upon reasonable request. Decisions regarding data sharing will be made on a case-by-case basis by the corresponding author considering data protection and other applicable regulations. Proposals may be submitted by the corresponding author.

ORCID

Christina Rautenberg https://orcid.org/0000-0002-0611-1372
Michael Lauseker https://orcid.org/0000-0002-6662-7127
Jennifer Kaivers https://orcid.org/0000-0003-3255-721X

REFERENCES

1. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. JCO. 2011;29(5):487-494.
2. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.
3. Schroeder T, Wegener N, Lauseker M, et al. Comparison between upfront transplantation and different pretreatment cytoreductive
treatment approaches in patients with high-risk myelodysplastic syndrome and secondary acute myelogenous leukemia. *Blood Marrow Transplant*. 2019;25(8):1550-1559.

4. Rautenberg C, Gemming U, Stepanow S, et al. Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemia. *Am J Hematol*. 2021;96(1).

5. Kröger N. Induction, bridging, or straight ahead: the ongoing dilemma of allografting in advanced myelodysplastic syndrome. *Blood Marrow Transplant*. 2019;25(8):e247-e249.

6. Kroeger N, Sockel K, Wolschke C, et al. Prospective multicenter phase 3 study comparing 5-azacytidine (5-Aza) induction followed by allogeneic stem cell transplantation versus continuous 5-Aza according to donor availability in elderly MDS patients (55–70 years) (VidazaAllo Study). *Blood*. 2018;132(Supplement 1):208.

7. Schmid C, de Wreeede LC, van Biezen A, et al. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. *Haematologica*. 2018;103(2):237-245.

8. Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. *JCO*. 2011;29(9):1190-1197.

9. Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. *Blood*. 2013;122(10):1813-1821.

10. Araki D, Wood BL, Othus M, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? *JCO*. 2016;34(4):329-336.

11. Zhou Y, Othus M, Araki D, et al. Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. *Leukemia*. 2016;30(7):1456-1464.

12. Gastos-Oreiro M, Perez-Corrall A, Martínez-Laperche C, et al. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hematopoietic stem cell transplantation. *Eur J Haematol*. 2014;93(3):239-246.

13. Kayser S, Benner A, Thiede C, et al. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. *Blood Cancer J*. 2016;6(7):e449.

14. Dillon R, Hills R, Freeman S, et al. Molecular MRD status and outcome after transplantation in NPM1-mutated AML. *Blood*. 2020;135(9):680-688.

15. Lussana F, Caprioli C, Stefanoni P, et al. Molecular detection of minimal residual disease before allogeneic stem cell transplantation predicts a high incidence of early relapse in adult patients with NPM1 positive acute myeloid leukemia. *Cancers*. 2019;11(10):1455.

16. Karas M, Steinerova K, Lysak D, et al. Pre-transplant quantitative determination of npm1 mutation significantly predicts outcome of allogeneic hematopoietic stem cell transplantation in patients with normal karyotype AML in complete remission. *Anticancer Res*. 2016;36(10):5487-5498.

17. Anthias C, Dignan FL, Morilla R, et al. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hematopoietic SCT in AML. *Bone Marrow Transplant*. 2014;49(5):679-683.

18. Thol F, Gabdoulline R, Liebich A, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. *Blood*. 2018;132(16):1703-1713.

19. Hourigan CS, Dillon LW, Gui G, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. *J Clin Oncol*. 2020;38(12):1273-1283.

20. Cilloni D, Renneville A, Hermite F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. *J Clin Oncol*. 2009;27(31):5195-5201.

21. Kwon M, Martínez-Laperche C, Infante M, et al. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms’ tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism. *Blood Marrow Transplant*. 2012;18(8):1235-1242.

22. Lange T, Hubmann M, Burkhardt R, et al. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. *Leukemia*. 2011;25(3):498-505.

23. Rautenberg C, Pechtel S, Hildebrandt B, et al. Wilms' Tumor 1 Gene expression using a Standardized European LeukemiaNet-certified assay compared to other methods for detection of minimal residual disease in myelodysplastic syndrome and acute myelogenous leukemia after allogeneic blood stem cell transplantation. *Blood Marrow Transplant*. 2018;24(11):2337-2343.

24. Rautenberg C, Gemming U, Pechtel S, et al. Prognostic impact of peripheral blood WT1 mRNA expression in patients with MDS. *Biol Blood Marrow Transplant*. 2019;13(9):11-1-8.

25. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127(20):2391-2405.

26. Chenoweth BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. *Blood*. 2006;108(2):419-425.

27. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. *Biol Blood Marrow Transplant*. 2009;15(12):1628-1633.

28. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. *Blood*. 2012;120(12):2454-2465.

29. Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. *Blood*. 2018;131(12):1275-1291.

30. Ino K, Fuji S, Tajima K, et al. Clinical utility of Wilms’ Tumor 1 monitoring in patients with myeloid malignancy and prior allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2017;23(10):1780-1787.

31. Candoni A, Tiberi M, Tofoletti E, et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. *Eur J Haematol*. 2009;82(1):61-68.

32. Papamannuili E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. *N Engl J Med*. 2016;374(23):2209-2221.

33. Nazha A, Cortes J, Faderl S, et al. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at presentation mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemia. *Am J Hematol*. 2012;97(8):1242-1245.

34. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. *J Clin Oncol*. 2018;36(26):2684-2692.

35. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. *N Engl J Med*. 2020;383(7):617-629.
36. Di Grazia C, Pozzi S, Geroldi S, et al. Wilms tumor 1 expression and pre-emptive immunotherapy in patients with acute myeloid leukemia undergoing an allogeneic hemopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2016;22(7):1242-1246.

37. Rautenberg C, Bergmann A, Germing U, et al. Prediction of response and survival following treatment with azacitidine for relapse of acute myeloid leukemia and myelodysplastic syndromes after allogeneic hemopoietic stem cell transplantation. *Cancers*. 2020;12(8):2255.

38. Rautenberg C, Bergmann A, Pechtel S, et al. Wilm's Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation. *Bone Marrow Transplant*. 2020;56(2):442-450.

39. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. *N Engl J Med*. 2019;381(18):1728-1740.

40. Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia With FLT3-Internal Tandem Duplication Mutation (SORTMAIN). *J Clin Oncol*. 2020;38(26):2993-3002.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Rautenberg C, Lauseker M, Kaivers J, et al. Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS. *Eur J Haematol*. 2021;107:283–292. [https://doi.org/10.1111/ejh.13664](https://doi.org/10.1111/ejh.13664)